Skip to content
DataLookout
Menu

NCT06162572

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 26 versions: 25 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites reduced: 56 → 52 locations
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 2 of 16 entries
  2. Minor Trial sites reduced: 63 → 56 locationsv25
  3. Minor Enrollment target: 101 to 102v24
  4. Minor Enrollment target: 100 to 101v23
  5. Minor Enrollment target: 74 to 100v22
Show 19 earlier versionsHide 19 earlier versions
  1. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 176 to confirmed 74
    • Study sites: 73 to 63
    v21
  2. Minor Study sites revised (73)v20
  3. Minor Site details revised at 1 of 73 sitesv19
  4. Minor Eligibility criteria revised
    • Site details revised at 11 of 73 sites
    v18
  5. Minor Site details revised at 1 of 73 sitesv17
  6. Minor Site details revised at 3 of 73 sitesv16
  7. Minor Site details revised at 3 of 73 sitesv15
  8. Minor Site details revised at 6 of 73 sitesv14
  9. Minor Site details revised at 3 of 73 sites
    • Eligibility criteria expanded, about 4 words
    v13
  10. Minor Site details revised at 2 of 73 sitesv12
  11. Minor Site details revised at 4 of 73 sitesv11
  12. Minor Study sites revised (73)v10
  13. Minor Study sites revised (73)v9
  14. Minor Study sites: 72 to 73
    • Start date changed from estimate of Aug 31, 2024 to Aug 7, 2024
    v7
  15. Notable Start date: Jul 26, 2024 to Aug 31, 2024
    • Study sites: 8 to 72
    v6
  16. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 7, 2024 to Jul 26, 2024
    • Site details revised at 8 of 8 sites
    v5
  17. Minor Study sites: 0 to 8v4
  18. Notable Start date: Apr 30, 2024 to Jun 7, 2024v3
  19. Minor Start date: Apr 1, 2024 to Apr 30, 2024v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence and severity of dose-limiting toxicities (DLTs) during the first 2 cycles of combination treatment
Timeframe: Through the end of the Cycle 2 (each cycle is 21 days)
Incidence and severity of adverse events (AEs)
Timeframe: From the signed informed consent form (ICF) to 30 days after the last dose
Incidence and severity of serious adverse events (SAEs)
Timeframe: From the signed ICF to 120 days after the last dose
Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays
Timeframe: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
Adverse Events (AEs) Leading to Permanent Treatment Discontinuation
Timeframe: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
Objective Response (OR)
Timeframe: Until study termination (approximately 2 years)

Secondary (16)

Objective Response (OR)
Best Overall Response (BOR)
Duration of Response (DoR)
Disease Control (DC)
6-month Durable Response (6-month DR)
Show 11 moreShow less
Progression-Free Survival (PFS)
Plasma or serum concentration of S095018
Plasma or serum concentration of S095024
Plasma or serum concentration of S095029
Incidence and titer of anti-drug antibodies (ADA) directed against S095018
Incidence and titer of anti-drug antibodies (ADA) directed against S095024
Incidence and titer of anti-drug antibodies (ADA) directed against S095029
Incidence and severity of adverse events (AEs)
Incidence and severity of serious adverse events (SAEs)
Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays
Adverse Events (AEs) Leading to Permanent Treatment Discontinuation

Arms and interventions

S095018 (anti-TIM3 antibody) in combination with cemiplimabExperimental

Part A: Combination-therapy safety lead-in

S095024 (anti-CD73 antibody) in combination with cemiplimabExperimental

Part A: Combination-therapy safety lead-in

S095029 (anti-NKG2A antibody) in combination with cemiplimabExperimental

Part A: Combination-therapy safety lead-in

S095018 (anti-TIM3 antibody) RDE in combination with cemiplimabExperimental

Part B: Randomized dose expansion

S095024 (anti-CD73 antibody) RDE in combination with cemiplimabExperimental

Part B: Randomized dose expansion

S095029 (anti-NKG2A antibody) RDE in combination with cemiplimabExperimental

Part B: Randomized dose expansion

Cemiplimab (control arm)Active comparator

Part B: Randomized dose expansion

Drugs: S095018, S095024, S095029, S095018 Recommended Dose Expansion (RDE), S095024 RDE, S095029 RDE, Cemiplimab

Sites

52 sites in 13 countries

Brazil 11, Italy 9, Spain 6, France 5, Australia 4, Hungary 3, United Kingdom 3, United States 3, Austria 2, Belgium 2, Taiwan 2, Hong Kong 1, Romania 1